Effective drugs for obesity have been available for a very long time. Administer semaglutide (sold as Ozempic and Wegovy), which helps people improve weight-related health, including risk reduction heart attack or stroke while reducing the noise related to eating.
As the demand for semaglutide increases, so does claims that taking it is “cheating” on weight loss or the “easy way out.”
We don’t tell individuals who need statins to treat high cholesterol or drugs to regulate hypertension that they’re cheating or taking the simple way out.
We also needs to not shame people taking semaglutide. It is a medication used to treat diabetes and obesity that have to be used long-term and has risks and unwanted side effects in addition to advantages. Prescribed to treat obesity, it is given alongside advice on food regimen and exercise.
How it’s working?
Semaglutide is glucagon-like peptide-1 receptor agonist (GLP-1RA). This implies that the body produces its own glucagon-like peptide-1 hormone, the so-called GLP-1 briefly, work higher.
When this happens, GLP-1 is secreted by intestinal cells detects increased nutrient levels after a meal. This stimulates the production of insulin, which lowers blood sugar levels.
GLP-1 also slows gastric emptying, which causes a feeling of satiety and reduces hunger and the sensation of reward after eating.
GLP-1 receptor agonist (GLP-1RA) drugs corresponding to Ozempic improve the motion of the body’s own GLP-1 by mimicking and prolonging its effects.
Some studies have shown that less GLP-1 is released after meals adults with obesity or type 2 diabetes in comparison with adults with normal glucose tolerance. So less GLP-1 circulating in your blood means you do not feel as full after eating and feel hungry again more quickly in comparison with individuals who produce more.
GLP-1 has a very short half-life of approx two minutes. Therefore, GLP-1RA drugs are designed to have a very long half-life of approx seven days. Therefore, semaglutide is given as a weekly injection.
What can users expect? What does the research say?
Higher doses of semaglutide are prescribed for the treatment of obesity in comparison with the treatment of type 2 diabetes (as much as 2.4 mg vs. 2.0 mg per week).
An enormous group randomized, controlled trialscalled the STEP studies, all tested weekly injections of two.4 mg of semaglutide compared with various interventions or placebo medications.
Weekly injections of semaglutide 2.4 mg were consistently present in studies lasting 1.3–2 years. led to six–12% greater weight loss in comparison with placebo or alternative interventions. The mean change in body weight depended on the duration of treatment and the length of the statement period.
fcm82/Shutterstock
Weight loss attributable to semaglutide also results in: lowering systolic and diastolic blood pressure by roughly 4.8 mmHg and a couple of.5 mmHg, respectively, which suggests a reduction triglyceride levels (a sort of fat within the blood) i improvement of physical functions.
Another recent study in adults with pre-existing heart disease and obesity but without type 2 diabetes found that adults receiving weekly injections of semaglutide 2.4 mg 20% less risk specific cardiovascular events, including nonfatal heart attack, stroke, or death from heart problems, after three years of follow-up.
Who is eligible for semaglutide?
Australia’s regulator, the Therapeutic Goods Administration (TGA), did so approved semaglutide, sold under the name Ozempic, for the treatment of type 2 diabetes.
However, as a result of shortages, the TGA has advised doctors not to prescribe the brand new Ozempic medicines for off-label use, for instance for the treatment of obesity, and the Pharmaceutical Benefits Scheme does not currently subsidize the medication’s off-label use.
TGA has approved Wegovy for the treatment of obesity but is currently not available in Australia.
Once available, doctors will have the option to prescribe the drugs semaglutide used to treat obesity combined with lifestyle interventions (including food regimen, physical activity and psychological support) in adults with obesity (BMI 30 or more) or individuals with a BMI of 27 or more who even have weight-related health complications.
What else must you remember during Ozempic treatment?
Checking details regarding Intervention components of the STEP trialyou possibly can see that the participants put a lot of effort and time. In addition to taking medications, in most studies participants attended short lifestyle counseling sessions with dietitians or other health care professionals a minimum of every 4 weeks.
The support sessions were designed to assist people stick with consuming 2,000 kilojoules (500 calories) less of their energy needs and doing 150 minutes of exercise each day. moderate or intense physical activitylike a brisk walk, dancing and gardening every week.
The STEP studies varied in other elements, with follow-up periods starting from 68 to 104 weeks. The purpose of this study was to show the impact of adding the drug to other lifestyle advice.
Elena Nichizhenova/Shutterstock
AND review of obesity drug research found that individuals reported needing less cognitive behavior training to assist them maintain their reduced energy intake. This is one aspect where drug treatment may make compliance somewhat easier. Not feeling hungry and “turning off” environmental cues to eating may mean less support in setting goals, self-monitoring food intake, and avoiding things that trigger eating.
But what are the unwanted side effects?
Semaglutide unwanted side effects switch on nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain.
In one study these caused drug discontinuation in 6% of individuals, but interestingly also in 3% of individuals taking placebo.
More serious unwanted side effects included gallbladder disease, acute pancreatitis, hypoglycemia, acute kidney disease, and injection site reactions.
To reduce the danger or severity of unwanted side effects, Drug doses are increased very slowly for months. Studies indicate that after full dose and response is achieved, it must be used long-term.
Given this long-term commitment and related high out-of-pocket drug costsrelating to taking semaglutide to treat obesity, it could actually certainly not be considered a “scam”.